Seedlabs

ADHDMono: A CDH2-Led Gene Panel for Familial ADHD

A genetic test for children with family histories of ADHD to find single-gene causes for the condition.

A targeted sequencing panel, led by CDH2 and other synaptic-adhesion genes, that tests children with early-onset, familial, or consanguineous-background ADHD for monogenic causes, returning a diagnosis plus recessive-inheritance counseling for the family.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderClinical genetic diagnostics for pediatric psychiatry and medical genetics

Concept

A clinical-grade next-generation sequencing panel built around CDH2 and a curated set of cadherin/synaptogenesis genes, ordered for children whose ADHD is early-onset, runs in the family, or comes from a consanguineous background. The single wedge: identify the monogenic, recessively inherited ADHD subtype that the new paper proved exists. The report returns (a) pathogenic variant calls, (b) recessive-inheritance counseling facts for parents (e.g., 25% recurrence risk for homozygous carriers), and (c) a plain-language annotation that this subtype involves reduced tyrosine hydroxylase and dopamine and that the equivalent knock-in mice responded to methylphenidate — framed as mechanistic context for first-line therapy, not a treatment guarantee. The panel is deliberately scoped to high-yield referrals (family history, parental consanguinity, early onset) rather than all ADHD.

Why now

Paper [0] establishes the first monogenic, non-syndromic ADHD: a homozygous CDH2 p.H150Y missense mutation segregating with ADHD in a consanguineous pedigree, with CRISPR knock-in mice carrying the human mutation recapitulating hyperactivity (increased traveling distance, velocity, and mobility time in open-field tests) that was modified by methylphenidate. The mechanism is coherent and measurable — impaired furin cleavage of the N-cadherin prodomain, smaller presynaptic vesicle clusters, a smaller readily releasable pool, reduced mEPSC frequency, and reduced tyrosine hydroxylase and dopamine in ventral midbrain and prefrontal cortex — so a positive result explains the biology, not just the label. GWAS work [3] has mapped 27 common risk loci but cannot give any individual family a causal answer; the monogenic finding [0] makes sequencing actionable for the subset of families where it changes counseling. Expected yield is modest (a single pedigree so far), which is exactly why the product targets consanguineous and familial referrals rather than population screening.

Written by GLM · 13 Oct 2026

AI assessment

Backed by 2 papers87

A highly focused clinical diagnostic panel targeting a newly discovered monogenic cause of ADHD, offering clear value for high-risk familial and consanguineous populations.

Evidence strength
4/5
The idea is directly grounded in a specific, high-quality study demonstrating a causal link between a CDH2 mutation and ADHD, validated by CRISPR knock-in mice and biochemical assays.
Market pull
3/5
While the target population (consanguineous/familial) is small, the urgency for genetic counseling and definitive diagnosis in these cohorts creates a viable, high-value niche.
Novelty & moat
5/5
Unlike the listed ideas which focus on monitoring or general subtyping, this is the first specific application of a monogenic ADHD discovery into a diagnostic product.
Feasibility
5/5
Targeted NGS panels are a mature technology; implementing a specific gene list for a known mutation is a straightforward technical task for any clinical lab.
Wedge clarity
5/5
The wedge is exceptionally sharp: targeting only children with early-onset, familial, or consanguineous ADHD to maximize the hit rate of a rare mutation.
Simplicity / focus
5/5
The product is a single, well-defined diagnostic test with a specific report output, avoiding the 'platform' trap.

Scored by Gemma 4 · 13 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Soroka University Medical Centerorganization

    Serves the Negev Bedouin population, the community in which the causal CDH2 mutation was identified; its medical genetics institute could offer the panel and recessive-inheritance counseling directly to affected families.

  • Centogenecompany

    Rare-disease sequencing company with a strong footprint in Middle Eastern markets where consanguinity raises the yield of recessive monogenic ADHD; the panel fits its existing neurodevelopmental test portfolio.

  • Clalit Health Servicesorganization

    Israel's largest HMO runs genetic counseling services for consanguineous families; a validated familial-ADHD panel gives its counselors a concrete test where previously none existed.

  • GeneDxcompany

    High-volume exome lab; adding a curated CDH2/synaptic-adhesion ADHD panel converts currently unreturned variants into reportable findings for familial cases.

  • CHADDorganization

    The main ADHD patient-advocacy organization could use the panel's counseling outputs to inform families with multiple affected members that a genetic cause can now be tested for.

Research it builds on

  1. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains
    Ditte Demontis, G. Bragi Walters, Georgios I. Athanasiadis et al. · 2023 · 828 citations
    All ideas from this paper →
  2. CDH2 mutation affecting N-cadherin function causes attention-deficit hyperactivity disorder in humans and mice
    Daniel S. Halperin, Alexandra Stavsky, Rotem Kadir et al. · 2021 · 42 citations
    All ideas from this paper →
Leave feedback
feasibility